AlphAIalphai — Financial news for AI agents
quiverquant.comAUG 192 min read$PMI

Picard Medical Reports Second-Quarter 2026 Revenue Growth, Narrower Net Loss and Progress on Emperor Total Artificial Heart Development

Picard Medical reported Q2 2026 revenue growth of 39% to $3.0M, with a 16% reduction in net loss to $5.7M. Year-to-date revenue rose 50% to $4.1M, with $0.9M in gross profit. The company is advancing its Emperor Total Artificial Heart platform and focusing on operational improvements. PMI completed a 1-for-50 reverse stock split to comply with NYSE American listing standards.

Original reporting
quiverquant.com
Published Aug 19, 2026, 9:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 11:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Picard Medical Reports Second-Quarter 2026 Revenue Growth, Narrower Net Loss and Progress on Emperor Total Artificial Heart Development — source image
Source · quiverquant.com
Decision brief

The 30-second read

$PMINeutralMed
01

Why it matters

The Q2 results show operational improvement but the company remains loss‑making and reliant on financing.

02

Market read

Earnings release provides fresh data for traders in the medical device niche; limited broader market relevance.

03

What to watch

Potential regulatory or reimbursement challenges for the Emperor TAH platform and the recent reverse split may affect liquidity.

Relevance 6/10Novelty 6/10Timing: Q2 2026 earnings release

Background

Picard Medical (PMI) is the parent of SynCardia, maker of the only FDA‑approved total artificial heart.

Company-level read

Ticker impact

$PMINeutralMedium confidence
Context

Picard Medical reported Q2 2026 revenue up 39% to $3.0M and net loss narrowing to $5.7M, the first release of these results.

Expected impact

Modest upside potential if investors price in the revenue growth; limited downside risk.

Evidence & confidence

First‑time earnings disclosure with better-than‑prior‑year metrics, but absolute figures are modest for a micro‑cap.

Market effects

Sector

Positive signal for the niche total artificial heart sector, may attract niche biotech interest.

Regional

Limited to U.S. small‑cap biotech segment; no broader market effect.

Global

Minimal global impact due to company size and niche product focus.

Counterpoint

What could challenge this read

Despite revenue growth, ongoing net losses and need for additional financing could pressure the stock.

Key entities

  • company
    Picard Medical, Inc.

    Parent company reporting Q2 2026 financials.

  • subsidiary
    SynCardia Systems, LLC

    Manufacturer of the SynCardia Total Artificial Heart.

Read at source← All news

Related articles

AUG 24
$PMIMed

Biotech Gainers: PMI Revenue Growth, SDOT Earnings Surge, CAPR FDA Update, GRI Data Drive Gains

Picard Medical (PMI) rose 40% after reporting Q2 revenue growth of 39% to $3.0M. Sadot Group (SDOT) surged 100% despite zero revenue, with net income up to $35.2M. Capricor Therapeutics (CAPR) gained 11% after FDA extended review for deramiocel. GRI Bio (GRI) climbed 10% with Phase 2a data selected for ERS 2026. Biomea Fusion (BMEA) rose 14% after completing Phase 2 diabetes trial enrollment. Yarrow Bioscience (YARW) advanced 12% with Graves' disease trial updates.

rttnews.com3 min
JUL 27
$PMIMedAI 8/10

PMI revenues top $11bn as IQOS grows share in Global Travel Retail

Philip Morris International reported Q2 2026 net revenues of $11.2bn, up 10.4% year on year and 7.6% organically. Gross profit rose to $7.7bn and operating income to $4.5bn. Smoke-free shipments increased 7.5%, with IQOS holding a 21.5% Global Travel Retail airport offtake share (Mar-May). PMI plans $1.4bn-$1.6bn capex for 2026.

dfnionline.com6 min
JUN 3
$BJDXMedAI 9/10

Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL

Healthcare stocks rose Tuesday on multiple biotech updates. Bluejay Diagnostics (BJDX) surged 100% after a strategic partnership with Argonaut to advance its Symphony diagnostic platform and announced a private placement up to $23.6M. Picard Medical (PMI) gained 60.33% after completing animal implant studies of its Emperor total artificial heart. Legend Biotech (LEGN) rose 42.22% ahead of EHA Phase 1 data. CUE climbed 18.93% with board changes. Cingulate (CING) rose 11.94% despite the FDA declin

finanzen.ch6 min
JUN 3
$BJDXMedAI 9/10

Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL

Healthcare biotech gainers on Tuesday included Bluejay Diagnostics (BJDX), which said it signed a strategic partnership with Argonaut to support its Symphony near-patient diagnostic platform; BJDX shares rose 100% to $4.34 and the company also announced a private placement up to $23.6M. Picard Medical (PMI) reported completed animal implant studies for its next-gen Emperor total artificial heart; shares rose 60.33% to $0.27. Legend Biotech (LEGN) said it will present Phase 1 data for LB2501 show

rttnews.com5 min
JUN 2
$PMIMedAI 8/10

Picard Medical / SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies

Picard Medical (NYSE American: PMI), parent of SynCardia, said it completed an acute in vivo implant study series of its next-generation Emperor Total Artificial Heart at the University of Arizona and Banner University Medical Center. Three procedures showed stable full circulatory support with no device-related intraoperative failures, using an independent dual-motor ventricular design. The Emperor TAH remains under development and is not FDA approved.

manilatimes.net4 min